Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Cancer Prev Res (Phila). 2015 Jan 20;8(3):249–257. doi: 10.1158/1940-6207.CAPR-14-0224

Figure 3.

Figure 3

Tumor mass was determined after engrafting mice with (A) BCaPT10 or (B) BCaPM-T10 cells and continuing a regimen of sterile deionized water ± 0.06% EGCG for (A) 2 or (B) 1 month(s). Data represent average tumor mass/mouse ± SD with n=8 mice/group. *p<0.05, **p<0.01 by unpaired t-test. (C, D) H&E staining of (A) late tumorigenic and (B) metastatic tumors from untreated and EGCG treated mice. (E) Mice (n=5/group) were engrafted with one of the individually isolated/purified NT BPH-1 derived prostate epithelial populations from previously untreated or EGCG treated mice for 2 months. The extent of malignant transformation was then examined (# of tumors formed). Data represent number of mice in which tumors were observed for that group.